PharmaBoardroom

IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs…

Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5…

With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar…

Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative…

Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer…

Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique…

Fabian Gerber of SIX Swiss Exchange, Switzerland's principal stock exchange, outlines the importance of life sciences companies to the exchange,…

Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to…

The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big…

Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in…

Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the…

Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy…